Mozenavir  (Synonyms: DMP-450)

Mozenavir (DMP 450) is an orally active and highly selective inhibitor of HIV-1 protease (K_i=0.3 nM). Mozenavir blocks the cleavage and processing of viral polyproteins, inhibiting the replication and maturation of HIV-1. Mozenavir is promising for research of HIV infection^[1][2][3].

536.66

C₃₃H₃₆N₄O₃

174391-92-5

O[C@H]([C@H]([C@H](N(C1=O)CC2=CC(N)=CC=C2)CC3=CC=CC=C3)O)[C@@H](CC4=CC=CC=C4)N1CC5=CC(N)=CC=C5

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Mamidala E, et al. In silico prediction of mozenavir as a potential drug for SARS-CoV-2 infection via binding multiple drug targets. Saudi J Biol Sci. 2022 Feb;29(2):840-847.  [Content Brief]

  [2]. Karpoormath R, et al. Novel PCU cage diol peptides as potential targets against wild-type CSA HIV-1 protease: synthesis, biological screening and molecular modelling studies[J]. Medicinal Chemistry Research, 2013, 22: 3918-3933.

  [3]. Hodge CN, et al. Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450. Chem Biol. 1996 Apr;3(4):301-14.  [Content Brief]